ATLANTA – The March 2013 issue of The Journal of Urology, the official journal of The American Urological Association, includes a study conducted by four physicians from Radiotherapy Clinics of Georgia (RCOG), a Vantage Oncology affiliate. This study, 25 Year Disease Free Survival Rate after Irradiation of Prostate Cancer Calculated with the Prostate Specific Antigen Definition of Recurrence Used for Radical Prostatectomy, is the first-ever to analyze 25 years of follow-up data after radiation therapy treatment for prostate cancer patients.
Frank Critz, M.D., founder and medical director at RCOG, the largest community-based prostate program in the United States, co-wrote this study along with three other RCOG physicians, James Benton, M.D., Philip Shrake, M.D., and Mark Merlin, M.D. The prostate program at RCOG is the only program of its kind to have gathered and maintained a clinical records database for all patients over a 30-year period in a consistent and comprehensive manner.
"This study, the longest after irradiation of prostate cancer, confirms using the surgical PSA definition (PSA <0.2 ng/ml) that results from this program are equal to that of radical prostatectomy, thus giving men a choice of treatment and after 15 year follow up if the PSA is <0.2, late recurrence will be rare."
This research study included 3,546 hormone naïve men with prostate cancer treated by I-125 implant followed by external beam radiation. The initial cohort was treated with retropubic implants, and as technology improved, the implant technique was changed to a transperineal template/ultrasound guided approach, which was the technique used in 2,875 of these men. Seventy three percent of men had no evidence of prostate cancer 25 years after this irradiation program. To compare like populations, this study compares patients treated between 1984-2000 to two previous prostatectomy studies which analyze 15 years of follow up data and a disease-free survival (DFS) calculation with a PSA<0.2. The surgical definition is much stricter than the one usually used in radiation therapy studies. Results showed comparable DFS at 10 (75 percent, 77 percent, 77 percent) and 15 years of follow up (73 percent, 68 percent, 75 percent). A sub analysis of patients treated with transperineal implants between 1995 and 2000 showed a 15 year disease-free survival (DFS) of 79 percent.
The analysis includes over 300 men whose prostate cancer recurred who were treated 16-25 years ago. Recurrences were PSA defined and results showed the majority of recurrences occurred within the first five years after treatment and no recurrences were noted15.5-25 years after treatment.
This study concludes that follow up evaluations are necessary for 15 years after treatment to fully understand the outcomes of any treatment for prostate cancer. Unlike a previous study on patients recurring after prostatectomy, this is the first to include interval censoring analysis when looking at time to recurrence. If a man's PSA is <0.20 ng/ml 15 years post treatment, later recurrence of the disease should be rare.
About Radiotherapy Clinics of Georgia
An affiliate of Vantage Oncology, Radiotherapy Clinics of Georgia was founded in 1982 and has earned a reputation for being one of the country's top prostate cancer treatment and research facilities because of its commitment to quality, use of the latest radiation technology and focus on research that enables it to treat men and women with different types of cancer, including breast, prostate, lung, colon, lymphatic and others. Radiotherapy Clinics of Georgia has treated 14,000 men for prostate cancer and has compiled its observations of these men, both before and after treatment, into one of the largest computerized databases on prostate cancer in the United States. For more information, visit www.rcog.com.
About Vantage Oncology
Founded in 2002, Vantage Oncology, LLC owns and operates 46 radiation oncology centers in 12 states. The Vantage network of affiliated and partnered medical groups has access to aggregated clinical information and best practices data from the treatment of approximately 1,100 patients per day. Vantage supports their affiliated physician partners including radiation oncologists, urologists, hematologist/oncologists, gynecological oncologist and surgeons by providing strategic planning, managed care contracting, information systems consulting, accounting resources, human resources and marketing services. As a byproduct Vantage's effective oversight of day-to-day operations, physicians are able to focus their efforts on patient care. For more information about Vantage Oncology, visit www.vantageoncology.com.
About The Journal of Urology®
Established in 1917, The Journal of Urology (www.jurology.com) is the official journal of the American Urological Association (www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.
The Journal of Urology